3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Meningioma
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Cancer Recurrent
1
Diffuse Intrinsic Pontine Glioma
1
Breast Neoplasms, Male
1
Interventions
Temozolomide
7
Radiotherapy
3
Everolimus
3
nimotuzumab
2
Erlotinib Hydrochloride
2
Cyclophosphamide
2
Bevacizumab
2
tovorafenib
1
ribociclib
1
palbociclib
1
olutasidenib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vinorelbine
1
Valproic Acid
1
Topotecan
1
TIC10 compound
1
Radiation
1
Proto-Oncogene Proteins c-akt
1
Phosphatidylinositol 3-Kinases
1
Panobinostat
1
Lomustine
1
Irinotecan
1
Injections
1
GDC-0084
1
Etoposide
1
Drug Therapy
1
Doxorubicin
1
Diphtheria-Tetanus Vaccine
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Diffuse Intrinsic Pontine Glioma
×
TIC10 compound
×
Clear all
NCT05009992
2025-12-17
PNOC022
University of California, San Francisco
Phase 2
Recruiting
360 enrolled